NASDAQ$WGS
GeneDx Holdings Corp · Q4 2025 earnings
Q4 2025 earnings · · Before market open
Briefing
GeneDx reported Q4 2025 revenue of $121.0M with adjusted net income of $4.4M; GAAP net loss was $17.7M.
GeneDx delivered Q4 revenue of $121.0M (+27% YoY, +37% excluding a 2024 payer recovery), with exome/genome revenue up 32% and volume up 34%. Adjusted gross margin was 71% and adjusted net income was $4.4M, while GAAP net loss was $17.7M (diluted loss $0.61). Cash and investments totaled $172.3M. Management reaffirmed FY2026 guidance for revenue of $540–$555M, 33–35% exome/genome growth, adjusted gross margin at least 70%, and positive adjusted net income.
- Q4 revenue $121.0M; exome/genome revenue $104.0M (+32% YoY).
- Adjusted net income $4.4M; GAAP net loss $17.7M.
- Exome/genome volumes 27,761 (+34% YoY), 47% of total tests.
- Reaffirmed FY2026 revenue $540–$555M and positive adjusted net income.
Headline financials
Revenue & EPS history
GeneDx Holdings Corp · Revenue · Quarterly
$121M
Forward guidance
FY2026 guidance: revenue $540–$555M, exome/genome revenue and volume growth of 33–35%, adjusted gross margin at least 70%, and positive adjusted net income.
Tailwinds
- 33–35% exome/genome growth targets sustained momentum from Q4 volume trends.
- Adjusted gross margin floor of 70% supports scaling of GeneDx Infinity platform.
- Expanded Medicaid coverage in eight additional states broadens addressable market.
Headwinds
- GAAP net loss in Q4 despite adjusted profitability.
- Adjusted operating expenses 68% of revenue versus 52% prior year.
- Prior-year results included $6.8M discrete payer recovery affecting comparisons.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q4 2025
-0.2%
Avg return
Earnings day
-7.5%
Avg return
5 days after
-10.6%
Avg return
30 days after
36%
5 / 14 earnings
Positive
+49.9%
Q3 2024
Best reaction
-42.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | -37.6% | -18.8% | |
| Q4 2025 | +6.1% | -2.9% | -18.4% | |
| Q3 2025 | +5.2% | +4.8% | +26.7% | |
| Q1 2025 | -42.8% | -43.4% | -39.1% | |
| Q3 2024 | +49.9% | +38.7% | +41.7% | |
| Q2 2024 | -10.6% | -10.7% | -3.6% | |
| Q1 2024 | -0.7% | +77.4% | +90.9% | |
| Q3 2023 | -1.1% | -20.7% | -2.2% | |
| Q2 2023 | -0.6% | -21.2% | -34.1% | |
| Q1 2023 | -5.6% | -22.2% | -24.3% | |
| Q3 2022 | -12.2% | -39.0% | -70.8% | |
| Q2 2022 | -1.2% | -51.0% | -58.8% | |
| Q1 2022 | +10.3% | +32.1% | +1.9% | |
| Q3 2021 | -2.5% | -9.2% | -39.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro